In an anticipated decision by the Judicial Panel on Multidistrict Litigation (“Panel”) regarding the consolidation of Zofran (ondansetron) litigation, on October 13, 2015, the Panel ordered that cases pending in several federal district courts to will be consolidated and transferred to the District of Massachusetts before Judge F. Dennis Saylor, IV. More than 50 Zofran cases are now pending in federal courts. An MDL consolidates lawsuits alleging similar claims—in this case, that Zofran (ondansetron)’s manufacturer GlaxoSmithKline marketed the anti-nausea drug “off label,” and failed to warn doctors and patients that it could cause birth defects—and centralizes them under one judge for the purpose of expediting discovery and maintaining consistent pretrial proceedings. The Panel rejected GlaxoSmithKline’s argument to consolidate in the Eastern District of Pennsylvania.
Plaintiffs’ law firm Grant & Eisenhofer has been representing mothers and families in Zofran (ondansetron) MDL No. 2657 since the litigation’s inception, filing the first cases against the drug giant over allegations that Zofran (ondansetron) caused cleft palate and congenital heart defects in newborns after their mothers took the drug to treat morning sickness. If you or a loved one took Zofran (ondansetron) during your first trimester and your child was born with a congenital heart defect or cleft palate, you may be entitled to compensation for pain and suffering, medical costs, loss of income, emotional distress and other damages. Call us today at 877-978-0169 for a free, confidential legal consultation of your potential claim.